Tirzepatide vs semaglutide: what the head-to-head trials found

What are the key differences between tirzepatide and semaglutide?

Tirzepatide and semaglutide differ in the receptors they activate and how they are made. Tirzepatide activates the GIP and GLP-1 receptors and is a synthetic peptide (TGA public assessment report, or AusPAR, for Mounjaro, 20 September 2024). Semaglutide activates the GLP-1 receptor only (US Ozempic label, DailyMed, 10 June 2026), and it is produced using recombinant DNA technology in yeast and chemical modification (TGA assessment report for Ozempic, October 2020). The US Mounjaro label gives an elimination half-life of approximately 5 days for tirzepatide, and the US Ozempic label approximately 1 week for semaglutide, as estimates from human pharmacokinetic label data with no participant numbers stated in those passages, which do not describe any one person (DailyMed, 2 September 2026 and 10 June 2026).

The two molecules share one design feature. The Mounjaro label says tirzepatide has a C20 fatty diacid that enables albumin binding, albumin being the carrier protein in blood, and prolongs the half-life. The Ozempic label says the main protraction mechanism of semaglutide is albumin binding, facilitated by a C18 fatty di-acid (DailyMed, 2 September 2026 and 10 June 2026). Tirzepatide is a 39-amino-acid linear peptide with a C20 fatty diacid attached at position 20 (Coskun et al., Molecular Metabolism, 2018). Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 (US Ozempic label, DailyMed, 10 June 2026).

The receptor story is where they split. In laboratory binding studies, tirzepatide's affinity for the GIP receptor was comparable to native GIP, and its affinity for the GLP-1 receptor was approximately 5-fold weaker than native GLP-1; these are laboratory measurements with no participants, and the cell findings do not establish a human result (Coskun et al., Molecular Metabolism, 2018). The US Ozempic label says semaglutide selectively binds to and activates the GLP-1 receptor (DailyMed, 10 June 2026). The tirzepatide hub holds the wider record on the molecule.

Is tirzepatide better than semaglutide? What the head-to-head trials found

In SURMOUNT-5, an open-label trial in which 751 adults with obesity but without type 2 diabetes were assigned to tirzepatide or semaglutide for 72 weeks, the least-squares mean weight change was −20.2% against −13.7%, a group average that does not predict any one person's result (Aronne et al., NEJM, 2025). In SURPASS-2, which followed 1,879 adults with type 2 diabetes for 40 weeks in an open-label design, estimated mean HbA1c fell by 2.01 to 2.30 percentage points on tirzepatide against 1.86 on semaglutide, group results that do not predict any one person's outcome (Frías et al., NEJM, 2021).

Limits come first. Both trials were open-label, so participants and staff knew which drug was given. Both report group averages, which cannot say what happens in any one person. 'Better' also depends on the measure. In SURPASS-2, an open-label trial of 1,879 adults with type 2 diabetes, estimated weight differences were 1.9, 3.6 and 5.5 kg greater on tirzepatide across its three tirzepatide arms, and gastrointestinal events were the most common in both drugs: nausea 17 to 22% on tirzepatide and 18% on semaglutide, diarrhoea 13 to 16% and 12%, vomiting 6 to 10% and 8%, in an open-label trial in people with type 2 diabetes (Frías et al., NEJM, 2021). In SURPASS-2, an open-label trial of 1,879 adults with type 2 diabetes, serious adverse events were 5 to 7% on tirzepatide and 3% on semaglutide, group figures that do not predict an individual outcome (Frías et al., NEJM, 2021).

Among 18,386 propensity-score-matched US adults with overweight or obesity (from 41,222 identified) who received tirzepatide or semaglutide in formulations labelled for type 2 diabetes, on or off label, in an observational cohort that cannot show cause, on-treatment analysis found that people taking tirzepatide were more likely to reach 5%, 10% and 15% weight loss (hazard ratios 1.76, 2.54 and 3.24), the 12-month difference in percentage weight change was −6.9% (95% confidence interval −7.9% to −5.8%), gastrointestinal adverse events were similar, and follow-up ended by discontinuation in 55.9% of the tirzepatide group and 52.5% of the semaglutide group (Rodriguez et al., JAMA Internal Medicine, 2024). How the SURPASS and SURMOUNT programmes were built explains what each trial asked. The what-is page answers the wider questions about tirzepatide.

Is tirzepatide the same as Mounjaro, and what is the difference?

Tirzepatide is the active ingredient in Mounjaro, and Mounjaro is the brand name of the registered medicine that contains it. Tirzepatide is the generic name of the molecule. Mounjaro is the trade name for the product listed on the Australian Register of Therapeutic Goods, where the TGA register entry gives a registration date of 23 December 2022 (read 14 October 2026; TGA assessment report for Mounjaro, 20 September 2024). The product adds a registered formulation, manufacturing controls, Product Information and prescription-only status (schedule S4 in the Mounjaro Product Information published with that report, version dated August 2024, which a later version may have replaced), which an ingredient name does not carry. Neither name is stronger or weaker than the other.

The question 'which is better for weight loss, tirzepatide or Mounjaro?' mixes two levels of naming. The molecule is the same. What differs is the document around it: a registered medicine has an approved indication, a Product Information sheet and a sponsor answerable to the regulator. In the United States, the same molecule carries two brand names: Mounjaro, whose label lists type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes at high risk, and Zepbound, whose label lists weight reduction and obstructive sleep apnoea (US labels, DailyMed, 2 September 2026).

Comparing prices between brands is outside this page, which reports studies and records only. Where tirzepatide comes from traces how one research code became a generic name and then a brand.

Tirzepatide vs Ozempic: which is stronger, and which works better for weight loss?

Ozempic is a brand of semaglutide (US Ozempic label, DailyMed, 10 June 2026), so a tirzepatide-versus-Ozempic comparison is a tirzepatide-versus-semaglutide comparison. 'Stronger' is not an end point in the trials cited here, which report outcomes such as average weight change and HbA1c instead. SURPASS-2 reported greater HbA1c and weight reductions on tirzepatide than on semaglutide in an open-label, maker-funded trial of 1,879 adults with type 2 diabetes (Frías et al., NEJM, 2021), and SURMOUNT-5 reported −20.2% against −13.7% weight change in an open-label, maker-funded trial of 751 adults with obesity and no diabetes (Aronne et al., NEJM, 2025). The TGA Medicines Safety Update of 3 June 2025 lists Ozempic as approved for adults with type 2 diabetes and Wegovy for chronic weight management, and the TGA register entries read on 14 October 2026 show Ozempic registered on 28 August 2019 for type 2 diabetes, with a second entry on 18 August 2025 for adults with type 2 diabetes and chronic kidney disease.

That registration detail matters when you read 'Ozempic or Mounjaro for weight loss'. The first Ozempic register entry covers adults with insufficiently controlled type 2 diabetes (TGA register and assessment report for Ozempic, October 2020). Wegovy, the same molecule under another brand, was registered for chronic weight management on 1 September 2022 (TGA register and assessment report for Wegovy, finalised 4 September 2024), and its later entries are dated 26 February 2024, 19 December 2024 and 30 March 2026 (read 14 October 2026). The two semaglutide brands are different products with different registered uses.

The honest limit: the PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a trial that compared the Mounjaro brand with the Ozempic brand. Trials compare molecules in studied groups, and a comparison is only as wide as its trial population.

Is Mounjaro registered for weight loss in Australia? What the registration says

Yes, as a registered indication. The TGA register entry for Mounjaro records a decision date of 9 September 2024 and a registration date of 10 September 2024 for chronic weight management (read 14 October 2026; TGA assessment report for Mounjaro, 20 September 2024). The entry lists the indication for adults with an initial body mass index of 30 or more, or 27 to under 30 with at least one weight-related comorbid condition, described as an adjunct to a reduced-calorie diet and increased physical activity. Mounjaro first entered the register on 23 December 2022 for type 2 diabetes, and a further entry on 2 June 2025 adds obstructive sleep apnoea. Tirzepatide is in Schedule 4 (prescription only) of the Poisons Standard F2026L01327, read 14 October 2026.

The TGA's assessment report says its submission for chronic weight management included two Phase 3, double-blind, placebo-controlled studies, SURMOUNT-1 and SURMOUNT-2 (TGA AusPAR, 20 September 2024). SURMOUNT-1 randomised 2,539 adults with obesity or overweight and no diabetes, and mean weight change at week 72 was −15.0%, −19.5% and −20.9% across the three tirzepatide arms against −3.1% on placebo, group averages from a maker-funded trial that do not predict any one person's result (Jastreboff et al., NEJM, 2022).

The registration is about a specific medicine, supplied by prescription. The register entry names Mounjaro and does not describe any other material carrying the molecule's name.

Do you lose more muscle on semaglutide or tirzepatide?

The PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a head-to-head trial that measured whether lean mass falls more on semaglutide or on tirzepatide, so these sources give no direct answer. Lean mass is also not the same as muscle, because it includes organs, bone and fluids (Neeland et al., Diabetes, Obesity and Metabolism, 2024). In a 160-person body-scan substudy of SURMOUNT-1 in adults with obesity or overweight and no diabetes (124 on tirzepatide and 36 on placebo; 73% women; measured by dual-energy X-ray absorptiometry, DXA), whose abstract names no funder, tirzepatide participants lost 21.3% of body weight, 33.9% of fat mass and 10.9% of lean mass at week 72, against 5.3%, 8.2% and 2.6% on placebo, and about 75% of the weight lost was fat and 25% lean mass for both tirzepatide and placebo, a result from a selected substudy, not an individual body-composition prediction (Look et al., Diabetes, Obesity and Metabolism, 2025).

Neeland et al.'s 2024 Diabetes, Obesity and Metabolism review describes heterogeneous measures and populations in GLP-1-based therapy studies, so this page does not pool their lean-mass results into a range or rank the medicines from separate studies.

DXA (dual-energy X-ray absorptiometry) was the scan the substudy used to measure body composition (Look et al., 2025). An average does not predict any one person's body composition, and this page offers no advice on it.

Reta vs tirzepatide: how do retatrutide and tirzepatide compare?

Retatrutide is an agonist of three receptors (GIP, GLP-1 and glucagon) and tirzepatide of two, and the PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a head-to-head trial of the two. Each molecule's numbers belong to its own trial design. In the 48-week Phase 2, double-blind, placebo-controlled retatrutide trial of 338 adults with obesity, or overweight and a weight-related condition, the least-squares mean weight change in the higher arm was −24.2% against −2.1% on placebo, in a maker-funded Phase 2 trial that does not predict a Phase 3 result (Jastreboff et al., NEJM, 2023). In SURMOUNT-1, a 72-week trial of 2,539 adults with obesity or overweight and no diabetes, tirzepatide's higher arm lost 20.9% against 3.1% on placebo, a group average from a maker-funded trial that does not predict an individual result or establish a cross-trial ranking (Jastreboff et al., NEJM, 2022).

Those two numbers come from different trials with different lengths, populations and designs, so they cannot be subtracted. The retatrutide comparison page sets all three molecules side by side and tracks retatrutide's regulatory status. This page cites only the peer-reviewed Phase 2 report.

Is cagrilintide better than tirzepatide?

The PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a trial that compared cagrilintide with tirzepatide, so these sources cannot say that either is better. Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety, which is a different hormone from GIP and GLP-1. In a 26-week Phase 2 trial of 706 adults with overweight or obesity without diabetes in total: 506 assigned to cagrilintide, 99 to liraglutide and 101 to placebo, funded by the maker of semaglutide, mean weight reduction by the trial-product estimand (which assumes all participants were adherent) was 10.8% at the highest cagrilintide level, 9.0% with liraglutide and 3.0% with placebo, in a trial that included no tirzepatide arm (Lau et al., The Lancet, 2021).

The cagrilintide–semaglutide combination was tested in REDEFINE 1, a 68-week double-blind Phase 3a trial of 3,417 adults with obesity or overweight and no diabetes, with lifestyle interventions in all groups, in which the estimated mean weight change was −20.4% on the combination against −3.0% on placebo and gastrointestinal adverse events affected 79.6% on the combination against 39.9% on placebo, with no tirzepatide arm (Garvey et al., NEJM, 2025). The maker of semaglutide funded both studies. Their numbers sit beside SURMOUNT-1's tirzepatide result only as separate records.

What drug is similar to tirzepatide?

Other medicines in the same broad class are GLP-1 receptor agonists: semaglutide, dulaglutide and liraglutide. The TGA Medicines Safety Update of 3 June 2025 lists Ozempic and Wegovy (semaglutide), Trulicity (dulaglutide), and Victoza and Saxenda (liraglutide) as the GLP-1 receptor agonists marketed in Australia, and Mounjaro as the dual GIP/GLP-1 agonist marketed there at that date. The TGA's assessment report for Mounjaro records that liraglutide was first registered in Australia in 2010, dulaglutide in 2015 and semaglutide in 2019 (TGA AusPAR, 20 September 2024).

Retatrutide is an agonist of the GIP, GLP-1 and glucagon receptors and is still under study (Jastreboff et al., NEJM, 2023). Tirzepatide has also been tested head-to-head against dulaglutide. In that double-blind cardiovascular trial of 13,299 adults with type 2 diabetes and established cardiovascular disease, followed for a median of 210.1 weeks, tirzepatide was non-inferior for major cardiovascular events (hazard ratio 0.92, 95.3% CI 0.83 to 1.01), superiority was not established, and the result applies to that population only (US Mounjaro label, DailyMed, 2 September 2026). This page lists neighbours by mechanism; it does not rank them or suggest a substitute.

Is tirzepatide synthetic or natural, and how is a peptide different from tirzepatide?

Tirzepatide is synthetic. The TGA's assessment describes it as a synthetic peptide receptor agonist, engineered from the native sequence of GIP, a gut hormone, and modified to bind to both GIP and GLP-1 receptors (TGA assessment report for Mounjaro, 20 September 2024). A peptide is a short chain of amino acids, the building blocks of proteins. Tirzepatide is one peptide: a linear chain of 39 amino acids with a C20 fatty diacid attached, including two non-standard amino acids at positions 2 and 13 (Coskun et al., Molecular Metabolism, 2018). Tirzepatide is not separate from peptides; it is one.

The gut releases GIP and GLP-1 after food (TGA AusPAR, 20 September 2024). Tirzepatide is a designed relative of them, not a collected extract. Where tirzepatide comes from follows the route from edited hormone sequence to laboratory code. Semaglutide has a different route: yeast-made backbone, then chemical modification (TGA assessment report for Ozempic, October 2020).

What are GLP-1 medicines registered for, and what is semaglutide registered for?

The TGA Medicines Safety Update of 3 June 2025 states that Ozempic, Trulicity and Victoza are approved for the management of adults with type 2 diabetes, that Saxenda and Wegovy are approved for chronic weight management, and that Mounjaro is approved for both. The TGA register entries read on 14 October 2026 add later indications: for Ozempic on 18 August 2025 (adults with type 2 diabetes and chronic kidney disease), for Wegovy on 26 February 2024 (adolescents), 19 December 2024 (cardiovascular risk) and 30 March 2026 (a liver disease called MASH), and for Mounjaro on 2 June 2025 (obstructive sleep apnoea). Semaglutide is the active ingredient of Ozempic, registered on 28 August 2019 for adults with insufficiently controlled type 2 diabetes, and of Wegovy, registered for chronic weight management on 1 September 2022 (TGA register entries and assessment reports for Ozempic and Wegovy).

Registered uses differ by country. The US Ozempic label also lists reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (DailyMed, 10 June 2026). The US Zepbound label lists reducing excess body weight and maintaining the reduction in adults with obesity, or overweight with at least one weight-related comorbid condition, and treating moderate to severe obstructive sleep apnoea in adults with obesity (DailyMed, 2 September 2026).

A registered use is a regulator's decision about a product. It is not a statement about what any substance does for a reader.

What is known as the 'poor man's Ozempic'?

'Poor man's Ozempic' is an informal nickname, and the TGA, FDA and trial documents searched on 14 October 2026 did not define it. Elahi Vahed et al.'s 2026 International Journal of Obesity review inventories 23 articles on randomised berberine trials, but its abstract supplies neither a participant total nor a breakdown of human clinical populations; those heterogeneous records do not establish equivalence to tirzepatide or semaglutide. In STEP 1, a double-blind, maker-funded trial of 1,961 adults with overweight or obesity and no diabetes, average body weight fell 14.9% with semaglutide against 2.4% on placebo over 68 weeks, a trial-group result that does not predict an individual outcome or establish a cross-trial ranking (Wilding et al., NEJM, 2021).

In SURMOUNT-1, a 72-week maker-funded trial of 2,539 adults with obesity or overweight and no diabetes, tirzepatide's higher arm lost 20.9% of body weight against 3.1% on placebo, a group mean that cannot predict an individual response or rank different products, populations and trial lengths (Jastreboff et al., NEJM, 2022). The PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a trial that compared berberine with semaglutide or tirzepatide. The comparison here shows only why a nickname cannot stand in for evidence.

Does any of this apply to research-use tirzepatide?

No. Each result on this page comes from a study of a trial drug product or a registered medicine, under clinical trial conditions or regulatory review (Aronne et al., NEJM, 2025; Frías et al., NEJM, 2021; TGA assessment report for Mounjaro, 20 September 2024). Research-use tirzepatide is a laboratory reference compound. It is not a medicine, is not a substitute for one, and is not for human or animal use. Australia's rules on compounded copies are separate again: the TGA's update of 18 June 2024 records that amendments to the Therapeutic Goods Regulations 1990 stop pharmacists compounding, and supplying to patients, medicines containing GLP-1 receptor agonist analogues compounded on or after 1 October 2024.

The catalogue lists tirzepatide reference material as laboratory stock, and its current certification is unverified. For the legal position of research peptides, the Australian law hub reads the Poisons Standard entry by entry.

Evidence limits

What do these comparisons not show?

Real-world cohorts such as Rodriguez et al. (JAMA Internal Medicine, 2024) carry the usual limits of observational data: who receives which drug is not random. A review article on lean mass (Neeland et al., 2024) describes wide spread between studies.

The PubMed abstracts and ClinicalTrials.gov records searched for this page on 14 October 2026 did not find a study of research-use material, and none of the sources cited here reports that any laboratory compound is a substitute for a registered medicine.